Want to inform investors similar to Dan Curran about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Dan Curran News
Jan 5, 2023
Lei Lei Wu News Reporter Takeda says in an interim Phase III analysis that its enzyme replacement therapy reduced instances of low blood platelet count for patients with a rare blood clot disorder known as congenital thrombotic thrombocytopenic purpura (cTTP) compared to standard of care plasma-based therapies. Dan Curran Next, it plans to file for authorization for the drug later this year “broadly — so not just in the US and EMA but also other jurisdictions globally,” Takeda head of rare genetics and hematology Dan Curran told Endpoints News. According to a press release Thursday morning, Takeda’s ERT, dubbed TAK-755, reduced low platelet count events by 60% compared to standard of care at the time of interim analysis. The study included around 60 patients, and the interim analysis used data on adolescents and adult patients, but not children under 12. Curran also noted that the ERT reduced instances of other symptoms associated with the disease, which manifests in a multitude of ways, but said that data would be presented at a future medical conference. TTP comes in two forms — congenital and immune, in which patients develop an immune response later in life that triggers the disease. TTP patients lack a protein that cleaves Von Willebrand factor, the glue that sticks platelets together to form clots and stop bleeding. Takeda’s ERT is a recombinant version of that protein called ADAMTS13. cTTP is exceedingly rare. Curran estimated that there are around 300 to 400 cases in the US. Patients with the disease experience bleeding in or under the skin, jaundice, extreme fatigue, vomiting, or other symptoms, and in the worst cases, stroke or seizures. In the study, patients who got Takeda’s ERT also experienced fewer side effects — 8.9% had adverse events on Takeda’s treatment compared to 47.7% on plasma-based infusions. “Many patients discontinue supplementation with plasma-derived products because of adverse events,” Curran noted, “so it’s incredibly important that you have a safe drug that will be used by patients continually.” He later added that, especially in the case of cTTP, in which many are diagnosed as children, it was important that patients could use the drug over their entire lifetime. Like other ERTs, Takeda’s ERT is dosed once every two weeks. Takeda acquired TAK-755 from its 2019 buyout of Shire (which acquired the ERT from its 2016 merger with Baxalta). Takeda is also testing the ERT in a Phase II study in iTTP and in a Phase Ib study in sickle cell disease, both of which Curran said will have data this year. AUTHOR John Carroll Editor & Founder Moderna CEO Stéphane Bancel made it clear early on in their M&A mapping phase that the biotech would be hunting the world for just the right mRNA-related deals to build the company into a global powerhouse. And nothing illustrates that strategy better than the $85 million tuck-in that the biotech is unveiling this morning. Bancel has struck a deal to buy Tokyo-based OriCiro Genomics and its work on cell-free synthesis and amplification of plasmid DNA, building up their set of tech for manufacturing aimed at scaling up production faster and carving weeks out of the process. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP News Reporter A month after the FDA rejected its neuroblastoma drug, the biotech Y-mabs said it will cut 35% of its workforce to save cash and focus on commercializing its lone approved product, Danyelza. The FDA rejected its drug omburtamab on Dec. 2, based on questions about the company’s clinical trial and after an advisory committee voted 16-0 against recommending the drug. The cuts will reduce operating expenses by 28%, and give Y-mabs enough cash to get through the first quarter of 2026. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Amgen started off the new year with a bang, joining forces with ADC player Synaffix and agreeing to dole out as high as $2 billion in Synaffix’s largest ADC licensing deal to date. The Dutch biotech — running in the same circles as ADC Therapeutics, Seagen, MacroGenics and Emergence Therapeutics — said Thursday that it secured a licensing deal with Amgen to develop new ADCs. As part of the deal, the Big Pharma gets access to Synaffix’s ADC platforms and technology, starting out with one ADC program. Amgen retains an option to exclusively license four more programs at a later date, but what those programs could be remains under wraps. Read More January 5, 2023 10:31 AM EST Kyle LaHucik Associate Editor GSK is tapping into WuXi Biologics’ T cell-engaging antibodies in a deal worth as much as $1.5 billion , as the UK drugmaker looks to follow suit of others in the T cell-engager field, which includes Amgen’s marketed cancer drug Blincyto. Only $40 million of the GSK deal will initially go to the Shanghai-based contract research and manufacturing giant, but with a biobuck bet above $1 billion, the Big Pharma sees lots of potential. The pact is a boon to WuXi, which suffered a loss of billions in market value after being placed on the US Department of Commerce’s unverified list last February. WuXi was removed from the list last month. Read More ENDPOINTS The year’s crop of US drug approvals won’t rival past vintages for quantity. But of the 45 drugs cleared for use by the FDA in 2022, a third are shaping up to be blockbusters, with high expectations for Lilly’s new diabetes drug, Bristol Myers Squibb’s TYK2 inhibitor and Gilead’s new HIV treatment. The promise of gene therapy became a reality in 2022, with new funding for the FDA to work through its backlog of applications, and three new approvals for bluebird bio (for beta thalassemia and early cerebral adrenoleukodystrophy) and CSL (for hemophilia B). With those approvals came new breakthroughs in price: The $2 million-plus treatment costs are likely to further test the bounds of the commercial market. Premium subscription required Beth Snyder Bulik Senior Editor McKinsey Consulting’s Brian Fox is joining Klick Group to boost its commercialization practice. The 18-year McKinsey veteran headed up the commercial life sciences practice there before joining Klick this week in a bid to drive its go-to-market capabilities with clients. Fox’s expertise spans product launches, sales force management, medical and corporate affairs, market access and clinical development. Klick already offers many of those services to biotech and pharma customers, but is looking to Fox to “turbocharge” those efforts, Klick co-founder and chairman Leerom Segal said. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.